Novus Therapeutics

$24.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$4.76 (+22.22%) Today
-$2.08 (-7.94%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell NVUS and other stocks, options, and ETFs commission-free!

About NVUS

Novus Therapeutics Inc. engages in the research and development of pharmaceutical products for patients with disorders of the ear, nose, and throat. The company operates under the surfactant and foam platforms. Read More The surfactant platform develops a treatment option for otitis media under OP0201 pipeline. The foam platform is used as a delivery vehicle for drugs to be administered into the ear canals, as well as the nasal and sinus cavities. The company was founded on March 26, 2004 and is headquartered in Irvine, CA. The listed name for NVUS is Novus Therapeutics, Inc. Common Stock.

CEO
David-Alexandre C. Gros
Employees
8
Headquarters
Irvine, California
Founded
2004
Market Cap
28.19M
Price-Earnings Ratio
Dividend Yield
Average Volume
56.15K
High Today
$27.32
Low Today
$19.94
Open Price
$20.98
Volume
216.64K
52 Week High
$27.32
52 Week Low
$4.50

Collections

NVUS Earnings

-$0.52
-$0.35
-$0.17
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 11, After Hours

You May Also Like